Characteristics of Smoothing Filters to Achieve the Guideline Recommended Positron Emission Tomography Image without Harmonization

Document Type: Original Article


1 Division of Radiology, Department of Medical Technology, Kyushu University Hospital, Fukuoka, Japan

2 Division of Radiology, Department of Medical Technology, Kyushu University Hospital

3 Department of Clinical Radiology, Kyushu University Hospital, Fukuoka, Japan

4 Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University


Objective(s): The aim of this study is to examine the effect of different smoothing filters on the image quality and SUVmax to achieve the guideline recommended positron emission tomography (PET) image without harmonization. Methods: We used a Biograph mCT PET scanner. A National Electrical Manufacturers Association (NEMA) the International Electrotechnical Commission (IEC) body phantom was filled with 18F solution with a background activity of 2.65 kBq/mL and a sphere-to-background ratio of 4. PET images obtained with the Biograph mCT PET scanner were reconstructed using the ordered subsets-expectation maximization (OSEM) algorithm with time-of-flight (TOF) models (iteration, 2; subset, 21); smoothing filters including the Gaussian, Butterworth, Hamming, Hann, Parzen, and Shepp-Logan filters with various full width at half maximum (FWHM) values (1-15 mm) were applied. The image quality was physically assessed according to the percent contrast (QH,10), background variability (N10), standardized uptake value (SUV), and recovery coefficient (RC). The results were compared with the guideline recommended range proposed by the Japanese Society of Nuclear Medicine and the Japanese Society of Nuclear Medicine Technology. The PET digital phantom was developed from the digital reference object (DRO) of the NEMA IEC body phantom smoothed using a Gaussian filter with a 10-mm FWHM and defined as the reference image. The difference in the SUV between the PET image and the reference image was evaluated according to the root mean squared error (RMSE). Results: The FWHMs of the Gaussian, Butterworth, Hamming, Hann, Parzen, and Shepp-Logan filters that satisfied the image quality of the FDG-PET/CT standardization guideline criteria were 8-12 mm, 9-11 mm, 9-13 mm, 10-13 mm, 9-11 mm, and 12- 15 mm, respectively. The FWHMs of the Gaussian, Butterworth, Hamming, Hann, Parzen, and Shepp-Logan filters that provided the smallest RMSE between the PET images and the 3D digital phantom were 7 mm, 8 mm, 8 mm, 8 mm, 7 mm, and 11 mm, respectively. Conclusion: The suitable FWHM for image quality or SUVmax depends on the type of smoothing filter that is applied.


Main Subjects


  1. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480-508.
  2. Ben-Haim S, Ell P. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009;50(1):88-99.
  3. Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh- Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38(11):2083-95.
  4. Bengtsson T, Hicks RJ, Peterson A, Port RE. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. J Nucl Med. 2012;53(4):530-7.
  5. Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009;50(Suppl 1):31S-42S.
  6. Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers HJ, et al. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med. 2007;48(11):1761-6.
  7. Dijkman BG, Schuurbiers OC, Vriens D, Looijen- SalamonM, Bussink J, Timmer-Bonte JN, et al. The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. Eur J Nucl Med Mol Imaging. 2010;37(11):2037-47.
  8. Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Revisiting the prognostic value of preoperative (18)F-fluoro- 2-deoxyglucose ((18) F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37(4):691-8.
  9. Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(1):27-38.
  10. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45(9):1519-27.
  11. Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging. 2007;34(3):392-404.
  12. Sunderland JJ, Christian PE. Quantitative PET/CT scanner performance characterization based upon the society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom. J Nucl Med. 2015;56(1):145-52.
  13.   Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40(7):985-96
  14.  Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guideline for tumor imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328-54.
  15. Fukukita H, Suzuki K, Matsumoto K, Terauchi T, Daisaki H, Ikari Y, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 2.0. Ann Nucl Med. 2014;28(7):693-705.
  16.  Rahmima A, Qi J, Sossi V. Resolution modeling in PET imaging: Theory, practice, benefits, and pitfalls. Med Phys. 2013;40(6):064301.
  17.  Quak E, Le Roux PY, Hofman MS, Robin P, Bourhis D, Callahan J, et al. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. Eur J Nucl Med Mol Imaging. 2015;42(13):2072-82.
  18. Makris NE, Huisman MC, Kinahan PE, Lammertsma AA, Boellaard R. Evaluation of strategies towards harmonization of FDG PET/CT studies in multicenter trials: comparison of scanner validation phantoms and data analysis procedures. Eur J Nucl Med Mol Imaging. 2013;40(10):1507-15.
  19. Quantitative imaging biomarker alliance. QIBA Profile. FDG-PET/CT for Response to Cancer Therapy. Available at: URL: http://qibawikirsnaorg/ images/1/1f/QIBA_FDG-PET_Profile_v113pdf; Accessed 28 July 2017.
  20. Standard PE. Imaging protocols and phantom test procedures and criteria: executive summary. Japan: Japanese Society of Nuclear Medicine Website; 2016.
  21. Tong S, Alessio AM, Kinahan PE. Noise and signal properties in PSF-based fully 3D PET image reconstruction: an experimental evaluation. Phys Med Biol. 2010;55(5):1453-73.
  22. Alessio A, Kinahan P. PET image reconstruction. Nucl Med. 2006;1:1-22.
  23. Saha GB. Basics of PET imaging physics, chemistry, and regulations. New York: Springer; 2014.